Suzanne D Turner1, Tara Gomes2, Ximena Camacho3, Zhan Yao3, Astrid Guttmann4, Muhammad M Mamdani2, David N Juurlink5, Irfan A Dhalla6. 1. Department of Family and Community Medicine, St. Michael's Hospital. 2. Li KaShing Knowledge Institute, St. Michael's Hospital ; Leslie Dan Faculty of Pharmacy, University of Toronto. 3. Institute for Clinical Evaluative Sciences. 4. Institute for Clinical Evaluative Sciences ; Division of Paediatric Medicine, Hospital for Sick Children ; Institute of Health Policy, Management and Evaluation, University of Toronto. 5. Institute for Clinical Evaluative Sciences ; Department of Medicine, University of Toronto ; Sunnybrook Research Institute, Toronto, Ont. 6. Institute for Clinical Evaluative Sciences ; Department of Medicine, University of Toronto ; Department of Medicine, St. Michael's Hospital.
Abstract
BACKGROUND: The incidence of neonatal opioid withdrawal is increasing in both Canada and the United States. However, the degree to which the treatment of pain with opioids, rather than the misuse of prescription opioids or heroin, contributes to the prevalence of neonatal opioid withdrawal remains unknown. METHODS: We conducted a retrospective, population-based, cross-sectional study between 1992 and 2011 in Ontario with 2 objectives. First, we determined the annual incidence of neonatal abstinence syndrome. Second, using data from a subset of women eligible for publicly funded prescription drugs, we determined what proportion of women who deliver an infant with neonatal abstinence syndrome were given a prescription for an opioid before and during pregnancy. RESULTS: The incidence of neonatal abstinence syndrome in Ontario increased 15-fold during the study period, from 0.28 per 1000 live births in 1992 to 4.29 per 1000 live births in 2011. During the final 5 years of the study, we identified 927 deliveries of infants with neonatal abstinence syndrome to mothers who were public drug plan beneficiaries. Of these mothers, 67% had received an opioid prescription in the 100 days preceding delivery, including 53.3% who received methadone, an increase from 28.6% in the interval spanning 1 to 2 years before delivery (p < 0.001). Prescription for nonmethadone opioids decreased from 38% to 17% (p < 0.001). INTERPRETATION: The incidence of neonatal opioid withdrawal in Ontario has increased substantially over the last 20 years. Most of the women in this cohort who delivered an infant with neonatal abstinence syndrome had received a prescription for an opioid both before and during their pregnancy.
BACKGROUND: The incidence of neonatal opioid withdrawal is increasing in both Canada and the United States. However, the degree to which the treatment of pain with opioids, rather than the misuse of prescription opioids or heroin, contributes to the prevalence of neonatal opioid withdrawal remains unknown. METHODS: We conducted a retrospective, population-based, cross-sectional study between 1992 and 2011 in Ontario with 2 objectives. First, we determined the annual incidence of neonatal abstinence syndrome. Second, using data from a subset of women eligible for publicly funded prescription drugs, we determined what proportion of women who deliver an infant with neonatal abstinence syndrome were given a prescription for an opioid before and during pregnancy. RESULTS: The incidence of neonatal abstinence syndrome in Ontario increased 15-fold during the study period, from 0.28 per 1000 live births in 1992 to 4.29 per 1000 live births in 2011. During the final 5 years of the study, we identified 927 deliveries of infants with neonatal abstinence syndrome to mothers who were public drug plan beneficiaries. Of these mothers, 67% had received an opioid prescription in the 100 days preceding delivery, including 53.3% who received methadone, an increase from 28.6% in the interval spanning 1 to 2 years before delivery (p < 0.001). Prescription for nonmethadone opioids decreased from 38% to 17% (p < 0.001). INTERPRETATION: The incidence of neonatal opioid withdrawal in Ontario has increased substantially over the last 20 years. Most of the women in this cohort who delivered an infant with neonatal abstinence syndrome had received a prescription for an opioid both before and during their pregnancy.
Authors: Andreea A Creanga; Jennifer C Sabel; Jean Y Ko; Cathy R Wasserman; Carrie K Shapiro-Mendoza; Polly Taylor; Wanda Barfield; Laurie Cawthon; Leonard J Paulozzi Journal: Obstet Gynecol Date: 2012-05 Impact factor: 7.661
Authors: Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink Journal: CMAJ Date: 2009-12-07 Impact factor: 8.262
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori Journal: Drug Saf Date: 2016-10 Impact factor: 5.606
Authors: Ekwutosi M Okoroh; Rebekah E Gee; Baogong Jiang; Melissa B McNeil; Beverly A Hardy-Decuir; Amy L Zapata Journal: Matern Child Health J Date: 2017-07
Authors: E Gomez-Pomar; A Christian; L Devlin; K T Ibonia; V A Concina; H Bada; P M Westgate Journal: J Perinatol Date: 2017-04-06 Impact factor: 2.521
Authors: Zoe F Cairncross; Jeremy Herring; Trevor van Ingen; Brendan T Smith; Pamela Leece; Brian Schwartz; Karin Hohenadel Journal: CMAJ Open Date: 2018-10-18
Authors: Nynke J van den Hoogen; Thomas J de Geus; Jacob Patijn; Dick Tibboel; Elbert A Joosten Journal: Pediatr Res Date: 2021-01-27 Impact factor: 3.756